Evaluation of the NCCLS M44-P Disk Diffusion Method for Determining Susceptibilities of 276 Clinical Isolates of Cryptococcus neoformans to Fluconazole

Journal of Clinical Microbiology

Volumn 42, Issue 1, 2004, Pages 380-383

  Pfaller, M A ^a   Messer, S A ^a   Boyken, L ^a   Rice, C ^a   Tendolkar, S ^a   Hollis, R J ^a   Diekema, D J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; FLUCONAZOLE; GLUCOSE; METHYLENE BLUE; MUELLER HINTON AGAR; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BROTH MICRODILUTION METHOD; CRYPTOCOCCUS NEOFORMANS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DIFFUSION; DILUTION; DISK DIFFUSION METHOD; DOSE RESPONSE; EVALUATION; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CRYPTOCOCCUS NEOFORMANS; DIFFUSION; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL;

BACTERIA (MICROORGANISMS); FILOBASIDIELLA NEOFORMANS;

EID: 0347093251     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.1.380-383.2004     Document Type: Article

References (26)

1. Aller, A. I., E. Martin-Mazuelos, F. Lozano, J. Gomez-Mateos, L. Steele-Moore, W. J. Holloway, M. J. Gutierrez, F. J. Recio, and A. Espinel-Ingroff. 2000. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob. Agents Chemother. 44:1544-1548.
2. Barry, A., J. Bille, S. Brown, D. Ellis, J. Meis, M. Pfaller, R. Rennie, M. Rinaldi, T. Rogers, and M. Traczewski. 2003. Quality control limits for fluconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue. J. Clin. Microbiol. 41:3410-3412.
3. Barry, A. L., and S. D. Brown. 1996. Fluconazole disk diffusion procedure for determining susceptibility of Candida species. J. Clin. Microbiol. 34:2154-2157.
4. Barry, A. L., M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoun, C. Knapp, R. P. Rennie, J. H. Rex, and M. G. Rinaldi. 2000. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38:3457-3459.
5. Barry, A. L., M. A. Pfaller, R. P Rennie, P. C. Fuchs, and S. D. Brown. 2002. Precision and accuracy of fluconazole susceptibility tests by broth microdilution, Etest, and disk diffusion methods. Antimicrob. Agents Chemother. 46:1781-1784.
6. Brandt, M. E., M. A. Pfaller, R. A. Hajjeh, R. J. Hamill, P. G. Pappas, A. L. Reingold, D. Rimland, D. W. Warnock, and The Cryptococcal Disease Active Surveillance Group. 2001. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob. Agents Chemother. 45:3065-3069.
7. Casadevall, A., E. D. Spitzer, D. Webb, and M. G. Rinaldi. 1993. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob. Agents Chemother. 37:1383-1386.
8. Hajjeh, R. A., M. E. Brandt, and R. W. Pinner. 1995. Emergence of cryptococcal disease: epidemiologic perspective 100 years after its discovery. Epidemiol. Rev. 17:303-320.
9. Hazen, K. C., and S. A. Howell. 2003. Candida, Cryptococcus, and other yeasts of medical importance, p. 1693-1711. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed. ASM Press, Washington, D.C.
10. Husain, A., M. M. Wagener, and N. Singh. 2001. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg. Infect. Dis. 7:375-381.
11. Jessup, C. J., M. A. Pfaller, S. A. Messer, J. Zhang, M. Tumerland, E. K. Mbidde, and M. A. Ghannoum. 1998. Fluconazole susceptibility testing of Cryptococcus neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients. J. Clin. Microbiol. 36:2874-2876.
12. Kontoyiannis, D. P., W. K. Peitsch, and B. T. Reddy. 2001. Cryptococcosis in patients with cancer. Clin. Infect. Dis. 32:145-150.
13. Mirza, S. A., M. Phelan, D. Rimland, E. Graviss, R. Hamill, M. E. Brandt, T. Gardner, M. Sattah, G. P. de Leon, W. Baughman, and R. A. Hajjeh. 2003. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin. Infect. Dis. 36:789-794.
14. Mitchell, T. G., and J. R. Perfect. 1995. Cryptococcosis in the era of AIDS 100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8:515-548.
15. National Committee for Clinical Laboratory Standards. 2001. Development of in vitro susceptibility testing criteria and quality control parameters. Approved guideline M23-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
16. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
17. National Committee for Clinical Laboratory Standards. 2003. Method for antifungal disk diffusion susceptibility testing of yeasts: proposed guideline M44-P. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Pappas, P. G., J. R. Perfect, G. A. Cloud, R. A. Larsen, G. A. Pankey, and D. J. Lancaster. 2001. Cryptococcosis in HIV-negative patients in the era of effective azole therapy. Clin. Infect. Dis. 33:690-699.
19. Perfect, J. R., and A. Casadevall. 2002. Cryptococcosis. Infect. Dis. Clin. N. Am. 16:837-874.
20. Pfaller, M. A., J. Zhang, S. A. Messer, M. E. Brandt, R. A. Hajjeh, C. J. Jessup, M. Tumerland, E. K. Mbidde, and M. A. Ghannoun. 1999. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob. Agents Chemother. 43:169-171.
21. Pfaller, M. A., D. J. Diekema, S. A. Messer, L. Boyken, and R. J. Hollis. 2003. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program. 2001. J. Clin. Microbiol. 41:1440-1446.
22. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry for the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole and itraconazole. Clin. Infect. Dis. 24:235-247.
23. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989.
24. Saag, M. S., J. R. Graybill, R. A. Larsen, P. G. Pappas, J. R. Perfect, and W. G. Powderly. 2002. Practice guidelines for the management of cryptococcal disease. Infectious Disease Society of America. Clin. Infect. Dis. 30:710-718.
25. Spitzer, E. D., S. G. Spitzer, L. F. Freundlich, and A. Casadevall, 1993. Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet 341:595-596.
26. Yildiran, S. T., A. W. Fothergill, D. A. Sutton, and M. G. Rinaldi. 2002. In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH 56592). Mycoses 45:378-383.